CN104825393B - 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法 - Google Patents
一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法 Download PDFInfo
- Publication number
- CN104825393B CN104825393B CN201510021961.5A CN201510021961A CN104825393B CN 104825393 B CN104825393 B CN 104825393B CN 201510021961 A CN201510021961 A CN 201510021961A CN 104825393 B CN104825393 B CN 104825393B
- Authority
- CN
- China
- Prior art keywords
- cefquinome sulfate
- preparation
- targeting liposomes
- pulmonary targeting
- cefquinome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 71
- KYOHRXSGUROPGY-OFNLCGNNSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrogen sulfate Chemical compound OS(O)(=O)=O.N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 KYOHRXSGUROPGY-OFNLCGNNSA-N 0.000 title claims abstract description 47
- 230000008685 targeting Effects 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 230000002685 pulmonary effect Effects 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 18
- 238000002347 injection Methods 0.000 claims abstract description 15
- 239000007924 injection Substances 0.000 claims abstract description 15
- 210000004072 lung Anatomy 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 230000001804 emulsifying effect Effects 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 238000004108 freeze drying Methods 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 8
- 239000008363 phosphate buffer Substances 0.000 claims description 8
- 238000010792 warming Methods 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 210000002969 egg yolk Anatomy 0.000 claims description 5
- 210000004907 gland Anatomy 0.000 claims description 5
- 239000000787 lecithin Substances 0.000 claims description 5
- 235000010445 lecithin Nutrition 0.000 claims description 5
- 238000002390 rotary evaporation Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 239000008215 water for injection Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims description 2
- 239000010409 thin film Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000004679 hydroxides Chemical class 0.000 claims 1
- 239000006193 liquid solution Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 210000000056 organ Anatomy 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 239000002552 dosage form Substances 0.000 abstract description 2
- 239000000273 veterinary drug Substances 0.000 abstract description 2
- 239000010408 film Substances 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 229950009592 cefquinome Drugs 0.000 description 8
- -1 hydrogen Sodium hydroxide Chemical class 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 239000003182 parenteral nutrition solution Substances 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 201000006509 pleuropneumonia Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000003307 reticuloendothelial effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000606807 Glaesserella parasuis Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 206010071301 Perihepatitis Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108700026460 mouse core Proteins 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003625 trehaloses Chemical class 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510021961.5A CN104825393B (zh) | 2015-01-16 | 2015-01-16 | 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510021961.5A CN104825393B (zh) | 2015-01-16 | 2015-01-16 | 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104825393A CN104825393A (zh) | 2015-08-12 |
CN104825393B true CN104825393B (zh) | 2017-11-10 |
Family
ID=53803865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510021961.5A Active CN104825393B (zh) | 2015-01-16 | 2015-01-16 | 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104825393B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012084951A1 (en) * | 2010-12-22 | 2012-06-28 | Bayer Animal Health Gmbh | Enhanced immune response in bovine species |
CN103637993A (zh) * | 2013-12-20 | 2014-03-19 | 湖北领盛制药有限公司 | 单分散纳米硫酸头孢喹肟脂质体制剂及其制备方法 |
CN103784404A (zh) * | 2014-02-18 | 2014-05-14 | 临沂大学 | 一种硫酸头孢喹诺脂质体及其制备方法 |
CN104000783A (zh) * | 2014-05-14 | 2014-08-27 | 河南牧翔动物药业有限公司 | 头孢喹肟脂质体 |
-
2015
- 2015-01-16 CN CN201510021961.5A patent/CN104825393B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012084951A1 (en) * | 2010-12-22 | 2012-06-28 | Bayer Animal Health Gmbh | Enhanced immune response in bovine species |
CN103637993A (zh) * | 2013-12-20 | 2014-03-19 | 湖北领盛制药有限公司 | 单分散纳米硫酸头孢喹肟脂质体制剂及其制备方法 |
CN103784404A (zh) * | 2014-02-18 | 2014-05-14 | 临沂大学 | 一种硫酸头孢喹诺脂质体及其制备方法 |
CN104000783A (zh) * | 2014-05-14 | 2014-08-27 | 河南牧翔动物药业有限公司 | 头孢喹肟脂质体 |
Non-Patent Citations (2)
Title |
---|
硫酸头孢喹肟脂质体的制备工艺;刘梦娇,等;《过程工程学报》;20131031;第13卷(第5期);第877-881页 * |
肺靶向利福平脂质体在小鼠体内的分布及抑杀菌效果观察;陈伟,等;《中国兽医学报》;20030331;第23卷(第2期);摘要部分以及第187页左栏第2段 * |
Also Published As
Publication number | Publication date |
---|---|
CN104825393A (zh) | 2015-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gulati et al. | Development of liposomal amphotericin B formulation | |
Schmitt | New methods of delivery of amphotericin B | |
CN101953792B (zh) | 伊立替康纳米长循环脂质体及其制备方法 | |
CN101703469B (zh) | 甲磺酸达氟沙星脂质体的制备方法及其产品 | |
CN103417479A (zh) | 一种人参皂苷Rg3脂质体及其制备方法 | |
CN103040748A (zh) | 一种培美曲塞二钠脂质体注射剂 | |
CN102716082B (zh) | 一种头孢西丁钠脂质体注射剂 | |
CN111228243B (zh) | 一种雾化吸入用妥布霉素脂质体及其制备方法 | |
CN103720658B (zh) | 肝素修饰的阿霉素脂质体制剂及其制备方法 | |
CN100486646C (zh) | 聚乙二醇-磷脂酰乙醇胺聚合物或它的药用酸加成盐及在制药中的应用 | |
CN104825393B (zh) | 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法 | |
CN109806273A (zh) | 泰拉霉素和加米霉素的复合溶液剂及其制备方法与应用 | |
CN101422435A (zh) | 替米考星脂质体制剂与制备方法 | |
CN102805729A (zh) | 一种长春氟宁脂质体制剂及其制备方法 | |
CN104983695A (zh) | 一种盐酸头孢噻呋脂质体冻干剂及其制备方法 | |
CN100348198C (zh) | 单唾液酸四已糖神经节苷脂脂质体复合物制剂 | |
CN101836995A (zh) | 复方磺胺间甲氧嘧啶钠多囊脂质体及其制备方法 | |
CN100479820C (zh) | 伊曲康唑脂质体及其制备方法 | |
CN105030730A (zh) | 多重靶向抗肿瘤复合制剂及其制备方法 | |
CN1756533B (zh) | 非聚乙二醇化的长期循环的脂质体 | |
CN105055318B (zh) | 一种具有man和wga修饰的双重靶向脂质体及其制备方法和应用 | |
CN114149469A (zh) | 钌配合物、狂犬病毒衍生肽和脂质体修饰的钌配合物 | |
CN102626381A (zh) | 一种拉氧头孢钠囊泡型磷脂凝胶注射剂 | |
CN102144969B (zh) | 一种依托泊苷纳米混悬液冻干制剂的制备方法 | |
CN105687136A (zh) | Peg化丹皮酚非离子表面活性剂泡囊及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 272073 Shandong city of Jining province high tech Zone Shixian Road No. 1688 Applicant after: AMICOGEN (CHINA) BIOPHARM CO.,LTD. Address before: 272073 Shandong city of Jining province Shixian Road No. 1688 Applicant before: SHANDONG LUKANG RECORD PHARMACEUTICALS Co.,Ltd. |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A lung targeted liposome preparation of cefquinoxime sulfate and its preparation method Effective date of registration: 20231027 Granted publication date: 20171110 Pledgee: Bank of Communications Ltd. Jining branch Pledgor: AMICOGEN (CHINA) BIOPHARM CO.,LTD. Registration number: Y2023980063066 |